S291: PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP

S291: PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP

Bibliographic Details
Main Authors:	D. J. Kuter, M. Efraim, Z. Kaplan, J. Mayer, P. Choi, A. G. Jansen, V. McDonald, R. Baker, R. Bird, M. Garg, J. Gumulec, M. Kostal, T. Gernsheimer, W. Ghanima, M. Yao, A. Daak, N. Cooper
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844056.11024.40

Similar Items

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
by: David Kuter, et al.
Published: (2023-08-01)

Rilzabrutinib placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
by: David J. Kuter, et al.
Published: (2023-10-01)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
by: Sibel Ucpinar, et al.
Published: (2023-07-01)

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.
by: Hong Ma, et al.
Published: (2013-01-01)

Expression of Bruton's tyrosine kinase in osteoclasts
by: Danks, L, et al.
Published: (2005)

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
by: Laura Airas, et al.
Published: (2024-04-01)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
by: Qi Wang, et al.
Published: (2015-02-01)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
by: Debora Basile, et al.
Published: (2019-06-01)

Lack of Bruton's tyrosine kinase results in osteoporosis, despite defects in osteoclast function
by: Danks, L, et al.
Published: (2007)

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response
by: Lee, K.-G., et al.
Published: (2013)

Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
by: Zhe Liu, et al.
Published: (2022-05-01)

Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci.
by: Sideras, P, et al.
Published: (1994)

Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
by: Horwood, N, et al.
Published: (2003)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01)

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
by: Issei Nakade, et al.
Published: (2023-11-01)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
by: Piyu Parth Naik
Published: (2022-01-01)

S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
by: Yan Shi, et al.
Published: (2023-08-01)

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
by: Qiu-Sha Huang, et al.
Published: (2023-08-01)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
by: Skye Montoya, et al.
Published: (2023-07-01)

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
by: Ragha V. Suresh, et al.
Published: (2023-08-01)

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
by: Haoran Wang, et al.
Published: (2022-09-01)

Elucidation of the role of Bruton's tyrosine kinase in toll-like receptor 3 signaling.
by: Yue, Shin Yen.
Published: (2008)

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
by: Omar Alkharabsheh, et al.
Published: (2021-02-01)

DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinaemia.
by: Vorechovský, I, et al.
Published: (1995)

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
by: Neeta Garg, et al.
Published: (2022-10-01)

Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production.
by: Horwood, N, et al.
Published: (2006)

Bruton's tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
by: O'Riordan, CE, et al.
Published: (2019)

498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.
by: Thomas Kartika, et al.
Published: (2024-04-01)

Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
by: Ye Liu, et al.
Published: (2023-12-01)

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
by: Yuqin Song, et al.
Published: (2023-10-01)

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies
by: Mohammed Alrouji, et al.
Published: (2023-10-01)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
by: Hyewon Cho, et al.
Published: (2020-10-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022-01-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)